Research programme: antibacterials - Peplin
Latest Information Update: 18 Jan 2010
At a glance
- Originator Neosil
- Developer Peplin
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Acne
Most Recent Events
- 12 Nov 2009 Peplin has been acquired by LEO Pharma
- 30 Sep 2009 Suspended - Preclinical for Acne in USA (unspecified route)
- 29 Oct 2008 Preclinical trials in Acne in USA (unspecified route)